Claro Advisors LLC Lowers Stock Position in Stryker Corporation $SYK

Claro Advisors LLC lessened its holdings in Stryker Corporation (NYSE:SYK) by 57.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,338 shares of the medical technology company’s stock after selling 1,813 shares during the quarter. Claro Advisors LLC’s holdings in Stryker were worth $529,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Mar Vista Investment Partners LLC raised its holdings in Stryker by 10.2% in the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after acquiring an additional 8,353 shares during the last quarter. United Services Automobile Association acquired a new position in Stryker in the 1st quarter valued at $2,857,000. AXS Investments LLC raised its holdings in Stryker by 13.7% in the 1st quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after acquiring an additional 1,062 shares during the last quarter. Hendley & Co. Inc. grew its stake in shares of Stryker by 60.3% during the 2nd quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,546,000 after buying an additional 5,274 shares during the period. Finally, Park Edge Advisors LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at $679,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 1.3%

Shares of Stryker stock opened at $357.76 on Thursday. The company has a fifty day moving average price of $376.08 and a 200 day moving average price of $381.07. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The stock has a market cap of $136.82 billion, a price-to-earnings ratio of 47.39, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same period in the prior year, the company earned $2.87 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

SYK has been the subject of several research reports. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a research note on Monday. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a research note on Wednesday, October 8th. Barclays boosted their price objective on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Truist Financial reissued a “hold” rating and set a $392.00 price objective (down from $407.00) on shares of Stryker in a research note on Monday. Finally, Needham & Company LLC boosted their price objective on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $433.37.

Insiders Place Their Bets

In other Stryker news, insider Viju Menon sold 500 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.90% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.